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Abstract
Background: There is a growing concern regarding the increase of antimicrobial resistant bacteria in companion
animals. Yet, there are no studies comparing the resistance levels of these organisms in European countries. The
aim of this study was to investigate geographical and temporal trends of antimicrobial resistant bacteria causing
urinary tract infection (UTI) in companion animals in Europe. The antimicrobial susceptibility of 22 256 bacteria
isolated from dogs and cats with UTI was determined. Samples were collected between 2008 and 2013 from 16
laboratories of 14 European countries. The prevalence of antimicrobial resistance of the most common bacteria was
determined for each country individually in the years 2012–2013 and temporal trends of bacteria resistance were
established by logistic regression.
Results: The aetiology of uropathogenic bacteria differed between dogs and cats. For all bacterial species, Southern
countries generally presented higher levels of antimicrobial resistance compared to Northern countries.
Multidrug-resistant Escherichia coli were found to be more prevalent in Southern countries. During the study
period, the level of fluoroquinolone-resistant E. coli isolated in Belgium, Denmark, France and the Netherlands
decreased significantly. A temporal increase in resistance to amoxicillin-clavulanate and gentamicin was observed
among E. coli isolates from the Netherlands and Switzerland, respectively. Other country-specific temporal
increases were observed for fluoroquinolone-resistant Proteus spp. isolated from companion animals from
Belgium.
Conclusions: This work brings new insights into the current status of antimicrobial resistance in bacteria isolated
from companion animals with UTI in Europe and reinforces the need for strategies aiming to reduce resistance.
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Background
Bacterial urinary tract infections (UTI) are frequently
diagnosed in dogs and are considered rare in cats [1, 2].
Lately, increased frequencies of UTI in cats have been
reported in some European countries [3–5] in particu-
larly when concurrent diseases are present [6].
Escherichia coli is the most frequent isolated bacteria
causing UTI in dogs and cats. Several studies show fre-
quencies greater than 30 % [7–9]. Other commonly isolated
bacteria genera include Staphylococcus spp., Enterococcus
spp., Proteus spp. and Klebsiella spp. [7–10].
Previous studies in the United Kingdom and in
Missouri-Columbia (USA) analysing the temporal trends
of antimicrobial resistance in small collections of bacterial
isolates from companion animal infections point to a sig-
nificant increase in antimicrobial resistance [11, 12]. Fur-
thermore, the emergence of multidrug-resistant bacteria
(isolates resistant to three or more antimicrobial categor-
ies) in companion animals is an increasing concern [11,
13–15]. This creates new therapeutic challenges in veterin-
ary medicine and is also a public health issue, since these
pathogens may be zoonotic [16] and companion animals
may play a role in the spread of resistant bacteria due to
their close contact to humans [14, 17].
Antimicrobial resistance may vary according to the
geographic location [9, 18]. Data on antimicrobial resist-
ance in bacteria isolated from companion animals with
UTI in Europe are not easily comparable due to differ-
ences in study design, such as variations in host species,
inclusion criteria and/or time period. Thus, it is difficult
to get a European overview of antimicrobial resistance
as seen in human medicine surveillance programmes
such as the European Antimicrobial Resistance Surveil-
lance Network [18].
Antimicrobial therapy in UTI should ideally rely on
susceptibility testing of the isolated bacteria [19]. Yet,
antimicrobials are frequently administered empirically
based on the presence of compatible clinical signs, urine
cytological findings and in the absence of urine culture
and are required to alleviate UTI symptoms while wait-
ing for antimicrobial susceptibility testing results [19].
Besides the pharmacokinetic-pharmacodynamic proper-
ties, the empiric antimicrobial selection should consider
the most likely causative agent as well as its regional
susceptibility patterns [8]. Moreover, according to the
World Organisation for Animal Health [20], veterinar-
ians should adopt strategies aimed at the reduction of
antimicrobial resistance. Therefore, current information
on the aetiology and antimicrobial resistance focused on
UTI is of crucial importance.
Under the umbrella of the European Society of Veter-
inary Nephrology and Urology, a multicenter retrospect-
ive study was launched in November 2013 with the goal
of getting antimicrobial resistance data on bacteria
isolated from companion animal with UTI across
Europe. A Urinary Tract Infection Resistance – Veterin-
ary Network (UTIR-VNet) was constituted with this
purpose in mind. Partial results were presented at the
annual Society meeting included in the 25th congress of
the European College of Veterinary Internal Medicine,
4–6 September 2014, Mainz, Germany. The aim of this
study was to determine the frequency of uropathogens
in dogs and cats with urinary tract infection in Europe
and to characterise the frequency and temporal trends of
antimicrobial resistance over a period of six years. We
hereby present a complete report and discussion of this
study.
Methods
Participating countries
Between January and September 2014, 16 veterinary
microbiology laboratories from 14 European countries
(Austria, Belgium, Denmark, France, Germany, Greece,
Italy, the Netherlands, Portugal, Serbia, Spain, Sweden,
Switzerland, United Kingdom), were invited to partici-
pate in this study (Fig. 1). Laboratories were requested
to send available retrospective data on animal species,
age and gender, bacterial identification and antimicrobial
susceptibility testing conducted in bacteria obtained
from dogs and cats with UTI between 2008 and 2013.
Samples were obtained with owners consent as part of
the routine care of canine and feline UTI.
Bacterial Isolates
The bacteria identification varied between laboratories.
Most laboratories used standard phenotypic tests, including
API, while others used techniques such as PCR and
MALDI-TOF. This discrepancy was particularly evident for
staphylococci, which were classified to either the species or
genus level depending on the laboratory.
Susceptibility testing
The following antimicrobials were included: amoxicillin-
clavulanate (AMC), ampicillin (AMP), cefotaxime (CTX),
cefovecin (CVN), cefoxitin (FOX), ceftazidime (CAZ),
cefpodoxime (CPD), ceftiofur (EFT), ciprofloxacin (CIP),
enrofloxacin (ENR), gentamicin (CN), marbofloxacin
(MAR), oxacillin (OX), penicillin (P) and trimethoprim/
sulfamethoxazole (SXT).
The retrospective nature of the study forced us to
include two in vitro antimicrobial susceptibility testing
methods. Laboratories from Austria, France, Germany,
Greece, Italy, the Netherlands, Portugal, Serbia, Spain,
United Kingdom, used standard disc diffusion method
according to Clinical Laboratory Standards Institute
(CLSI) guidelines [21], whereas Sweden (VetMIC, SVA,
Uppsala, Sweeden), Denmark and United Kingdom (COM-
PAN1F Sensititre panels, Thermo Fisher), Switzerland and
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Belgium (VITEK 2, BioMérieux) used broth microdilu-
tion method.
Human CLSI breakpoints [22] were used for interpret-
ation of minimal inhibitory concentration and disk diffu-
sion results for CAZ (30 μg), CTX (30 μg), and CIP (5 μg),
whereas veterinary CLSI breakpoints [23] were used for
AMC (30 μg), AMP (30 μg), CN (10 μg), CPD (10 μg),
ENR (5 μg), FOX (30 μg), MAR (5 μg), OX (1 μg), P
(10U), and SXT (25 μg). Clinical breakpoints from the
Societé Française de Microbiology [24] were used for EFT
(30 μg). Results for CVN (30 μg) were interpreted accord-
ing to the manufacturer guidelines. As seen in the human
European Antimicrobial Resistance Surveillance Network
(EARS-Net) report [18], when data on minimal inhibitory
concentrations or inhibition zone diameter were not avail-
able, the laboratories’ own interpretations (susceptible,
intermediate and resistant) were accepted. This was the
case for Spain, Serbia, and Germany that used contempor-
ary CLSI guidelines, for the United Kingdom that used the
breakpoints from the British Society of Antimicrobial
Chemotherapy [25] and for the Netherlands and
Switzerland (2008–2010) that used breakpoints recom-
mended by the Dutch Committee on Guidelines for Sus-
ceptibility testing [26].
Fig. 1 Participating countries in the Urinary tract infection antimicrobial resistance veterinary network – UTIR-VNet. Countries: AT- Austria; BE- Belgium;
DK- Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden; CH- Switzerland;
UK- United Kingdom
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Data analysis and statistical methods
Statistical analysis was performed using the SAS statis-
tical software package for Windows, version 9.3, (SAS
Institute Inc, Cary, North Carolina, USA).
The Fisher exact test was used to compare pathogen
frequencies by species or gender of the host, by simple/
multiple infection and by country. An alpha value of
0.05 was used.
Isolates were considered fully resistant when found to
be resistant according to the clinical breakpoint applied.
An isolate was considered susceptible when found to be
susceptible or intermediate according to the clinical
breakpoint applied. The antimicrobials included in this
study are known to be highly concentrated in the urine
so their report as susceptible may be appropriated for
isolates categorized as intermediate [19].
Regarding third generation cephalosporins (3GC),
laboratories tested different 3GC resistance surrogates.
Therefore, to evaluate the antimicrobial resistance to
3GC, an isolate was considered as 3GC resistant when it
was resistant to at least one of the five 3GC tested
(CTX, CAZ, CVN, EFT or CPD). The same rational was
applied to evaluate resistance to fluoroquinolones (FLU),
namely using ENR, CIP or MAR as a marker of resist-
ance. Methicillin-resistance in staphylococci was deter-
mined according to CLSI guidelines [23] using cefoxitin
or oxacillin to evaluate resistance depending on the
bacterial species considered. Yet, Germany and Spain
did not send data on methicillin-resistance. France did
not test staphylococci against oxacillin and thus did not
report methicillin-resistance regarding Staphylococcus
pseudintermedius (MRSP). The Netherlands did not
have data on staphylococci susceptibility to OX or FOX
but instead reported data on the detection of the mecA
gene by PCR. The frequency of methicillin-resistance
did not include staphylococci only identified to the
genus level.
Enterobacteriaceae were considered multidrug-resistant
(MDR) when fully resistant to three or more categories of
antimicrobials, namely AMC, 3GC, SXT, CN and/or FLU.
Unlike the MDR definition proposed by other authors [27],
intermediate isolates from this study were considered as
susceptible. This difference was applied because we are
considering drugs that can be highly concentrated in urine.
Furthermore, this approach will reduce any overestimation
of MDR frequency due to the use of different breakpoint
guidelines. Full-susceptibility (FullS) was defined as an iso-
late being susceptible for all the above-mentioned categor-
ies of antimicrobials. Since Belgium had no data available
on 3GC and the Netherlands had little data on CN, MDR
and FullS percentages do not include resistance to 3GC for
Belgium and resistance to CN for the Netherlands.
As a rule, statistical analysis was only done when at
least ten isolates for a specific organism-antimicrobial
agent combination were reported for a given country.
All frequencies are presented with a confidence interval
of 95 % (95 % CI).
Maps of European resistance distribution were drawn
considering the percentage of fully resistant isolates to the
considered antimicrobial agent, over the years 2012–2013.
A scale of colours was applied composed of six resistance
intervals after the example of EARS-Net surveillance
program reports [18].
Statistical analysis of temporal trends of antimicrobial
resistance for a specific organism-antimicrobial agent com-
bination were determined within each country. Temporal
trends were only determined for countries reporting data
on at least three consecutive years and ten isolates per year.
A SAS LOGISTIC regression, with the year as a continuous
variable and an alpha value of 0.05 was conducted.
Temporal trends of resistance were mainly determined for
E. coli since this was the most represented bacterial species.
Yet, temporal trends of AMC, FLU and SXT in Proteus
spp. were also determined for Belgium, France, the
Netherlands and Sweden.
Results
Overall, data on 22,256 uropathogenic bacteria were
obtained from 15,097 dog and 5963 cat positive urine
cultures. Table 1 summarises the numbers of bacterial
isolates obtained by year and country.
Considering the records containing information about
the age, dogs (n = 4425) and cats (n = 1514) had similar
Table 1 Total number of isolated bacteria by year and country
Countrya Year
2008 2009 2010 2011 2012 2013 Total
AT - - - - 144 185 329
BE - - 547 578 623 739 2487
DK 29 30 53 116 153 205 587
FR - - 620 733 780 995 3128
DE - 64 93 140 161 146 604
EL 24 29 13 11 32 43 152
IT - 36 29 36 77 65 243
NL 480 867 958 1132 1195 1307 5939
PT 77 54 57 34 32 45 299
RS 17 19 10 2 3 3 54
ES 14 23 27 40 47 79 230
SE 730 924 1071 1202 1355 1647 6929
CH 109 120 112 125 114 174 754
UK 31 44 81 117 126 122 521
Total 1511 2210 3671 4267 4842 5755 22256
aAT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT,
Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH,
Switzerland; UK, United Kingdom
Marques et al. BMC Veterinary Research  (2016) 12:213 Page 4 of 17
mean ages, namely 8.77 years (SD ± 4.04, 9.00 median,
6.00 IQR, range 0.1–20) and 8.82 years (SD ± 5.03, 8.50
median, 8.1 IQR, range 0.2–22) respectively. Gender was
only specified in 3885 records where 61.41 % (95 % CI
59.69–63.12 %, n = 1900/3094) of dogs and 48.29 % (95 %
CI 44.81–51.78 %, n = 382/791) of cats were females.
Among all urine cultures, 94.64 % (95 % CI 94.33–
94.94 %, n = 19932/21060) resulted in the growth of
bacterial pure cultures, with no significant difference
between cats and dogs (P = 0.1856). Both in dogs and cats,
E. coli was the most frequently identified bacteria and
accounted for 59.45 % (95 % CI 58.80–60.09 %, n = 13231/
22256) of all isolates. The frequency of the remaining bac-
terial species differed significantly between dogs and cats
(Table 2). Enterococcus spp. and Staphylococcus spp. fre-
quencies were higher in cats, whereas Proteus spp. and
Klebsiella spp. were more prevalent in dogs.
Considering the years 2012–2013, the major differ-
ences in E. coli (Table 3, Fig. 2) and Proteus spp. (Table 4,
Fig. 3) antimicrobial resistance frequencies were seen
between Northern (Denmark and Sweden) and Southern
(Italy, Greece, Portugal and Spain) countries.
The lowest frequencies of AMC resistance in E. coli
were detected in isolates from Denmark (2.88 %) and
Belgium (4.29 %). E. coli from Portugal (48.15 %) had a
significantly higher AMC resistance frequency (P < 0.05)
when compared with all countries except for Spain, Italy
and Greece (Table 3). Less than 15 % of Proteus spp.
were resistant to AMC in all countries with exception of
Portugal (50 %) and Spain (26.67 %) (Table 4).
E. coli resistance to 3GC had a similar distribution to
what was seen for AMC (Fig. 2). The highest 3GC resist-
ance frequencies were found in Southern countries,
namely Portugal (31.25 %), Italy (24.64 %) and Spain
(21.15 %) (Table 3). Proteus spp. 3GC resistance was
lower than 5 % in Austria, Denmark, Sweden, Switzerland,
United Kingdom and the Netherlands, whereas Portugal
(33.33 %) and Spain (15.38 %) were the countries with the
highest resistance levels (Table 4).
SXT resistance in Southern countries was higher than
25 and 45 % for E. coli and Proteus spp., respectively
(Tables 3 and 4; Figs. 2 and 3). Sweden and Denmark
had the lowest SXT resistance values (lower than 9 %).
The remaining included countries had frequencies
ranging between 10.21-21.13 % and 20–37.93 % in E. coli
and Proteus spp., respectively (Tables 3 and 4).
E. coli FLU resistance was higher in the Southern
countries and ranged from 29.03 % in Portugal to
31.88 % in Italy (Table 3). Concerning Proteus spp.,
Spain and Germany had around 50 % FLU resistance,
followed by Italy and Portugal with around 40 %
(Table 4). Sweden, Denmark, Belgium and the
Netherlands had less than 10 % FLU resistant E. coli.
Denmark, Sweden, United Kingdom and the Netherlands
had less than 10 % FLU resistant Proteus spp. (Figs. 2
and 3).
Table 2 Uropathogenic bacteria aetiology, single versus mixed infections and cat versus dog as host species
Organism Overall Single organism Mixed infections Dogs Cats
n %
(95 % CI)a
n %
(95 % CI)a
n %
(95 % CI)a
P n %
(95 % CI)a
n %
(95 % CI)a
P
Enterobacter spp. 308 1.38
(1.23–1.54)
244 1.22
(1.07–1.38)
64 2.75
(2.09–3.42)
<0.0001 194 1.21
(1.04–1.38)
114 1.81
(1.48–2.14)
0.0008
Enterococcus spp. 1506 6.77
(6.44–7.10)
1129 5.66
(5.34–5.99)
377 16.22
(14.72–17.72)
<0.0001 745 4.66
(4.34–4.99)
761 12.11
(11.31–12.92)
<0.0001
Escherichia coli 13231 59.45
(58.80–60.09)
12417 62.30
(61.62–62.97)
814 35.03
(33.09-36-97)
<0.0001 9506 59.51
(58.75–60.27)
3725 59.30
(58.08–60.51)
0.7832
Klebsiella spp. 478 2.15
(1.96–2.34)
400 2.01
(1.81–2.20)
78 3.36
(2.62–4.09)
<0.0001 385 2.41
(2.17–2.65)
93 1.48
(1.18–1.78)
<0.0001
Proteus spp. 1992 8.95
(8.58–9.33)
1770 8.88
(8.49–9.28)
222 9.55
(8.36–10.75)
0.2824 1869 11.70
(1.20–1.22)
123 1.96
(1.62–2.30)
<0.0001
Pseudomonas spp. 389 1.75
(1.58–1.92)
315 1.58
(1.41–1.75)
74 3.18
(2.47–3.90)
<0.0001 293 1.83
(1.63–2.04)
96 1.53
(1.22–1.83)
0.1249
Staphylococcus spp. 2893 13.00
(12.56–13.44)
2519 12.64
(12.18–13.10)
374 16.09
(14.60–17.59)
<0.0001 1836 11.49
(11.00–11.99)
1057 16.83
(15.90–17.75)
<0.0001
Streptococcus spp. 802 3.60
(3.36–3.85)
586 2.94
(2.71–3.17)
216 9.29
(8.11–10.47)
<0.0001 675 4.23
(3.91–4.54)
127 2.02
(1.67–2.37)
<0.0001
Other 657 2.95
(2.73–3.17)
552 2.77
(2.54–3.00)
105 4.52
(3.67–5.36)
- 471 2.95
(2.69–3.21)
186 2.96
(2.54–3.38)
-
a95 % CI, 95 % Confidence interval
n – Total number of isolates
P- P value obtained by Fisher exact test when comparing single versus mixed infections and cat versus dog as host. Statistically significant values are highlighted
in bold
Marques et al. BMC Veterinary Research  (2016) 12:213 Page 5 of 17
Overall, E. coli CN resistance was lower than 16 %
(Table 3). Regarding resistance to CN in Proteus spp. the
same resistance frequency occurred with the exception
of Portugal where a higher resistance frequency was
recorded (33.33 %) (Table 4).
E. coli from Portugal, Spain and Italy, and Proteus spp.
from Portugal showed the highest frequencies of MDR
(Tables 3 and 4). As expected, Portugal was one of the
countries with lowest FullS, both in E. coli (32.00 %) and
Proteus spp. (35.71 %). Italy had even lower FullS in
Table 3 Percentage of resistance in Escherichia coli by antimicrobial and country in 2012–2013
Countrya AMC 3GC FLU CN SXT Combined resistance
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % MDR
(95 % CI)b
[Stat. Dif.]c
% FullS
(95 % CI)b
[Stat. Dif.]c
AT 142 14.08
(8.36–19.81)
[a,b]
142 5.63
(1.84–9.43)
[a, b]
142 11.97
(6.63–17.31)
[a]
142 5.63
(1.84–9.43)
[a, b]
142 14.08
(8.36–19.81)
[a, b]
142 8.45
(3.88–13.03)
[a]
78.87
(72.16–85.59)
[a]
BE 840 4.29
(2.92–5.66)
[c]
0 -
-
769 6.63
(4.87–8.39)
[b]
840 1.67
(0.80–2.53)
[c]
839 10.37
(8.31–12.43)
[a]
769d 1.43d
(0.59–2.27)
-
85.05d
(82.52–87.57)
-
DK 206 2.88
(0.61–5.16)
[c]
208 4.33
(1.41–7.09)
[a, c]
208 2.88
(0.61–5.16)
[c]
208 1.92
(0.06–3.79)
[a, c]
208 8.17
(4.45–11.90)
[a, c]
208 2.88
(0.61–5.16)
[b]
88.94
(84.68–93.20)
[b, c]
FR 954 12.79
(10.67–15.91)
[a, d]
933 10.83
(8.83–12.82)
[b]
948 12.76
(10.64–14.89)
[a]
951 3.36
(2.22–4.51)
[a, d]
959 16.27
(13.93–18.60)
[b, d]
909 11.00
(8.97–13.04)
[a, c]
77.23
(74.50–79.95)
[a]
DE 153 11.76
(6.66–16.87)
[a, d]
152 11.84
(6.71–16.98)
[b, d]
153 16.34
(10.48–22.20)
[a, d]
153 1.96
(0.00–4.16)
[a, c, d]
153 17.65
(11.61–23.69)
[b, d, e]
152 8.55
(4.11–13.00)
[a]
67.76
(60.33–75.19)
[d]
EL 31 25.81
(10.40–41.21)
[b, d, e, f]
9 7R/2S
-
30 30.00
(13.60–46.40)
[d, e]
0 -
-
26 34.62
(16.33–52.90)
[e, f]
0 -
-
-
-
IT 69 26.09
(15.73–36.45)
[e, f]
69 24.64
(14.47–34.80)
[e]
69 31.88
(20.89–42.88)
[e]
69 14.49
(6.19–22.80)
[e]
69 28.99
(18.28–39.69)
[e, f]
69 28.99
(18.28–39.69)
[d]
63.77
(52.43–75.11)
[d, e, f]
NL 1461 10.81
(9.22–12.41)
[a]
1380 3.77
(2.76–4.77)
[a, c]
1457 4.94
(3.83–6.05)
[b, c]
81 3.70
(0.00–7.82)
[a, c, f]
1459 10.21
(8.66–11.77)
[a]
1380d 2.25d
(1.46–3.03)
-
81.30d
(79.25-83.36)
-
PT 27 48.15
(29.30-66.99)
[e]
32 31.25
(15.19-47.31)
[e]
31 29.03
(13.05-45.01)
[d, e]
30 10.00
(0.00-20.74)
[b, d, e, f]
31 32.26
(15.80-48.71)
[e, f]
25 24.00
(7.26-40.74)
[c, d, e]
32.00
(13.71–50.29)
[g, h]
RS 3 2R/1S - 2 1R/1S
-
3 0R/3S
-
3 0R/3S
-
3 1R/2S
-
2 1MDR
-
1Full-S
-
ES 60 31.67
(19.90–43.44)
[e, f]
52 21.15
(10.05–32.25)
[d, e]
61 29.51
(18.06–40.95)
[e]
46 15.22
(4.84–25.60)
[b, e]
60 26.67
(15.48–37.86)
[e, f]
37 29.73
(15.00–44.46)
[d, e]
43.24
(27.28–59.21)
[e, g]
SE 2091 6.98
(5.89–8.07)
[g]
2082 0
[f]
2091 1.05
(0.61–1.49)
[f]
2091 0.19
(0.00–0.38)
[g]
2091 4.97
(4.04–5.91)
[c]
2082 0.24
(0.03–0.45)
[f]
90.2
(88.92–91.48)
[b, h]
CH 133 10.53
(5.31–15.74)
[a, g]
133 8.27
(3.59–12.95)
[b, c]
132 13.64
(7.78–19.49)
[a, d]
132 6.82
(2.52–11.12)
[b, d, e, f]
131 13.74
(7.85–19.64)
[a, d, g]
130 10.00
(4.84–15.16)
[a, e]
83.08
(76.63–89.52)
[a, c]
UK 143 21.68
(14.92–28.43)
[b, f]
143 20.98
(14.31–27.65)
[d, e]
143 11.89
(6.58–17.19)
[a]
92 6.52
(1.48–11.57)
[a, e, f]
142 21.13
(14.41–27.84)
[b, f, g]
89 15.56
(8.07–23.04)
[a, e]
67.78
(58.12–77.43)
[a, d, f]
AMC amoxicillin clavulanate, 3GC third generation cephalosporins, FLU fluoroquinolones, CN gentamicin, SXT trimethoprim/sulfamethoxazole, MDR
multidrug-resistant, Full-S fully-susceptible
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden;
CH, Switzerland; UK, United Kingdom.
b95 % CI, 95 % Confidence interval
cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the same letter. Countries were compared by Fisher exact test
with an alpha value of 0.05. Countries with less than ten tested isolates were not compared. Regarding MDR and FullS, only countries tested for all the considered
antimicrobials were compared
n, Total number of Escherichia coli tested for the considered antimicrobial category
dMDR and FullS percentages do not include resistance to 3GC for Belgium and resistance to CN for the Netherlands
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Fig. 2 Percentage (%) of Escherichia coli antimicrobial resistance by antimicrobial and country in the years 2012–2013. Countries: AT- Austria;
BE- Belgium; DK- Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden;
CH- Switzerland; UK- United Kingdom. Multidrug-resistance considering combined resistance to three or more of the following antimicrobial
categories: AMC, 3GC, FLU, CN and SXT. Full-susceptibility (FullS) was defined as an isolate being susceptible for all the above-mentioned categories of
antimicrobials. Regarding multidrug-resistance and full-susceptibility frequencies, countries marked by asterisk: 3GC was not included for Belgium and
CN for the Netherlands. Thus, these frequencies may be underestimated when compared with the remaining countries
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Proteus spp. (16.67 %). Most of the remaining countries
had MDR levels lower than 10 %, with the exception of
MDR E. coli from United Kingdom (15.56 %) and France
(11 %). The highest E. coli and Proteus spp. FullS frequen-
cies were found in Denmark and Sweden (Tables 3 and 4).
Due to the limited number of Staphylococcus spp. iso-
lates available, the percentage of resistance to antimicro-
bials was determined on fewer countries for this group
of bacteria (Tables 5 and 6). In most countries, Staphylo-
coccus pseudintermedius was the most frequently
Table 4 Percentage of resistance in Proteus spp. by antimicrobial and country in 2012-2013
Countrya AMC 3GC FLU CN SXT Combined resistance
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % R
(95 % CI)b
[Stat. Dif.]c
n % MDR (95 % CI)b
[Stat. Dif.]c
% FullS
(95 % CI)b
[Stat. Dif.]c
AT 29 10.34
(0.00–21.43)
[a, b, c]
29 0
[a, b]
29 17.24
(3.49–30.99)
[a, b, c]
29 6.90
(0.00–16.12)
[a, b]
29 37.93
(20.27–55.59)
[a, b]
29 6.90
(0.00–16.12)
[a]
55.17
(37.07–73.27)
[a, b]
BE 143 2.10
(0.00–4.45)
[a, g]
0 -
-
135 28.15
(20.56–35.73)
[a, d]
155 9.68
(5.02–14.33)
[a]
154 35.06
(27.53–42.60)
[a, b]
125d 4.80d
(1.05-8.55)
-
57.60d
(48.94–66.26)
-
DK 31 0
[a, d]
31 0
[a, b]
31 0
[e, f]
31 0
[a, b]
31 6.45
(0.00–15.10)
[c]
31 0
[a, b]
93.55
(44.41–84.90)
[c]
FR 215 7.44
(3.93–10.95)
[b, d]
211 6.64
(3.28-9.99)
[a]
212 17,92
(12.76-23.09)
[b, g]
214 9.81
(5.83-13.80)
[a]
216 27.78
(21.80-33.75)
[a]
204 10.29
(6.12-14.46)
[a]
66.67
(60.20-73.14)
[a]
DE 10 0
[a, b, f]
10 10.00
(0.00–28.59)
[a, b, c]
10 50.00
(19.01–80.99)
[a, d]
10 0
[a, b, c]
10 20.00
(0.00–44.79)
[a, c, d]
10 0
[a, b]
50.00
(19.01–80.99)
[a, d]
EL 8 1R/7S
-
0 -
-
8 4R/4S
-
0 -
-
7 4R/3R
-
0 -
-
-
-
IT 12 0
[a, b, c]
12 8.33
(0.00–23.97)
[a, b, c]
12 41.67
(13.77–69.56)
[a, d, g]
12 8.33
(0.00–23.97)
[a, b, c]
12 66.67
(39.99–93.34)
[b, e]
12 8.33
(0.00–23.97)
[a, b, c]
16.67
(0.00–37.75)
[d]
NL 261 6.13
(3.22–9.04)
[a, b, e]
244 2.87
(0.77–4.96)
[a]
260 8.85
(5.39–12.30)
[c, e, h]
17 11.76
(0.00–27.08)
[a, c]
260 27.31
(21.89–32.72)
[a]
243d 3.29d
(1.05–5.54)
-
69.96d
(64.19–75.72)
-
PT 14 50.00
(23.81–76.19)
[e]
15 33.33
(9.48–57.19)
[c, d]
15 40.00
(15.21–64.79)
[a, g, i]
15 33.33
(9.48–57.19)
[c]
15 46.67
(21.42–71.91)
[a, e]
14 42.86
(16.93–68.78)
[c]
35.71
(10.61–60.81)
[b, d, e]
RS 1 0R/1S
-
1 1R/0S
-
1 0R/1S
-
1 0R/1S
-
0 -
-
0 -
-
-
-
ES 15 26.67
(4.29–49.05)
[c, e, f]
13 15.38
(0.00–35.00)
[a, d]
15 53.33
(28.09–78.58)
[d, i]
9 2R/7S
-
15 53.33
(28.09–78.58)
[b, d, e]
7 2MDR
-
4Full-S
-
SE 170 2.35
(0.07–4.63)
[a, f, g]
169 0
[b, e]
170 0.59
(0.00–1.74)
[f]
170 0.59
(0.00–1.74)
[b]
170 7.06
(3.21–10.91)
[c]
169 0
[b]
91.12
(86.84–95.41)
[c]
CH 17 0
[a, b, f]
17 0
[a, e]
17 23.53
(3.37–43.69)
[a, g, h, I, j]
17 5.88
(0.00–17.07)
[a, b, c]
17 35.29
(12.58–58.01)
[a, e]
17 0
[a, b]
64.71
(41.99–87.42)
[a, e]
UK 16 12.50
(0.00–28.70)
[a, b, f]
16 0
[a, e]
16 0
[b, e, f, j]
11 0
[a, b, c]
15 33.33
(9.48–57.19)
[a, e]
10 0
[a, b]
70.00
(41.60–98.40)
[a, c, e]
AMC amoxicillin clavulanate, 3GC third generation cephalosporins, FLU fluoroquinolones, CN gentamicin, SXT trimethoprim/sulfamethoxazole, MDR
multidrug-resistant, FullS fully-susceptible
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden;
CH, Switzerland; UK, United Kingdom.
b95 % CI, 95 % Confidence interval.
cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the same letter. Countries were compared by Fisher exact test
with an alpha value of 0.05. Countries with less than ten tested isolates were not compared. Regarding MDR and FullS, only countries tested for all the considered
antimicrobials were compared
n, Total number of Proteus spp. tested for the considered antimicrobial category
dMDR and FullS percentages do not include resistance to 3GC for Belgium and resistance to CN for the Netherlands
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Fig. 3 Percentage (%) of Proteus spp. antimicrobial resistance by antimicrobial and country in the years 2012–2013. Countries: AT- Austria; BE- Belgium; DK-
Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden; CH- Switzerland; UK- United
Kingdom. Multidrug resistance considering combined resistance to three or more of the following antimicrobial categories: AMC, 3GC, FLU, CN and SXT.
Full-susceptibility was defined as an isolate being susceptible for all the above-mentioned categories of antimicrobials. Regarding multidrug-resistance and
full-susceptibility frequencies, countries marked by asterisk: 3GC was not included for Belgium and CN for the Netherlands. Thus, these frequencies may be
underestimated when compared with the remaining countries
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isolated followed by coagulase negative staphylococci
(CoNS) (Table 5). In general, the overall antimicrobial
resistance levels in Southern countries were higher than
in Northern countries (Fig. 4) as seen in Gram-negative
bacteria (Figs. 2 and 3).
Besides the limited number of staphylococci, methicillin-
resistance results were also limited due to the identification
only to genus level or lack of testing the appropriate
antimicrobial surrogate. Denmark and Sweden showed the
lowest S. pseudintermedius methicillin-resistance (MRSP)
(0 and 1.15 %, respectively). The remaining countries had
MRSP frequencies higher than 8 %, attaining 50 % in Italy.
Methicillin-resistance was also high in CoNS (Table 5).
Staphylococci SXT resistance ranged from 2.77 to
63.16 % and showed similar geographical distribution to
Gram-negative bacteria (Fig. 4). Among the participating
countries, Staphylococci FLU resistance frequencies
were higher in Italy (42.11 %) and again lower in Sweden
(1.54 %) and Denmark (1.96 %), with the remaining
countries varying between 6.59 and 26.92 % (Table 6).
Italy, Austria, Germany and Switzerland CN resistant
staphylococci frequencies ranged between 26.32 and
9.76 % while the remaining countries had less than 6 %
(Table 6).
Regarding resistance temporal trends, most countries
had no significant changes in E. coli resistance over the
Table 5 Staphylococcus spp. and methicillin-resistance by country in 2012–2013
Staphylococci species by country Methicillin-resistance within each group
Countrya N SA SP CoPS CoNS SPP MRSA MRSP MRCoNS
%
(95 % CI)b
%
(95 % CI)b
%
(95 % CI)b
%
(95 % CI)b
%
(95 % CI)b
n
tested
R %
(95 % CI)b
n
tested
R %
(95 % CI)b
n
tested
R %
(95 % CI)b
AT 78 7.69
(1.78–13.61)
19.23
(10.48–27.98)
6.41
(0.97–11.85)
56.41
(45.41–67.41)
10.26
(3.52–16.99)
5 1R/4S
-
15 33.33
(9.48–57.19)
43 27.91
(14.50–41.31)
BE 122 14.75
(8.46–21.05)
52.46
(43.60–61.32)
0
-
32.79
(24.46–41.12)
0
-
18 5.56
(0–16.14)
64 12.50
(4.40–20.60)
40 25.0
(11.58–38.42)
DK 52 1.92
(0–5.66)
53.85
(40.30–67.40)
1.92
(0–5.66)
28.85
(16.53–41.16)
13.46
(4.18–22.74)
1 1S
-
27 0
-
15 46.67
(21.42–71.91)
FR 242 8.26
(4.80–11.73)
72.73
(67.12–78.34)
0
-
19.01
(14.06–23.95)
0
-
20 40.0
(18.53–61.47)
0 -
-
46 17.39
(6.44–28.34)
DE 64 4.69
(0–9.87)
50.0
(37.75–62.25)
0
-
39.06
(27.11–51.02)
6.25
(0.32–12.18)
0 -
-
0 -
-
0 -
-
EL 10 0
-
10.0
(0–28.59)
0
-
0
-
90
(71.41–100)
- -
-
1 1R
-
- -
-
IT 19 0
-
94.74
(84.70–100)
0
-
5.26
(0–15.30)
0
-
- -
-
18 50.0
(26.90–73.10)
0 -
-
NL 365 4.93
(1.12–2.71)
47.95
(42.82–53.07)
0
-
47.12
(42.0–52.24)
0
-
0 -
-
174 10.92
(6.29–15.55)
172 0.58
(0–1.72)
PT 7 1SA
-
4SP
-
0CoPS
-
0CoNS
-
2SPP
-
1 1R
-
4 2R/2S
-
0 -
-
RS 0 -
-
-
-
-
-
-
-
-
-
- -
-
- -
-
- -
-
ES 13 0
-
0
-
15.38
(0–35.0)
46.15
(19.05–73.25)
38.46
(12.02–64.91)
- -
-
- -
-
0 -
-
SE 325 8.62
(5.56–11.67)
53.54
(48.12–58.96)
2.46
(0.78–4.15)
32.31
(27.22–37.39)
3.08
(1.20–4.95)
28 0
-
174 1.15
(0–2.73)
105 4.76
(0.69–8.84)
CH 46 4.35
(0–10.24)
52.17
(37.74–66.61)
4.35
(0–10.24)
34.78
(21.02–48.55)
4.35
(0–10.24)
2 0R/2S
-
20 10.00
(0–23.15)
15 66.67
(42.81–90.52)
UK 32 12.50
(1.04–23.96)
53.13
(35.84–70.41)
6.25
(0–14.64)
18.75
(5.23–32.27)
9.38
(0–19.47)
3 1R/2S
-
12 8.33
(0–23.97)
3 1R/2S
-
Staphylococci identification varied according to the country. Some countries identified staphylococci to species level, others to genus level and others included
data on the coagulase test. Thus, the staphylococci results were grouped as follows: 1. Staphylococcus aureus (SA); 2. Staphylococcus pseudintermedius (SP); 3.
coagulase positive staphylococci (CoPS), 4. coagulase negative staphylococci (CoNS) and 5. other staphylococci (SPP). Group 2 includes staphylococci identified
only as CoPS or staphylococci species known to be coagulase positive other than SA and SP. Group 3 includes staphylococci identified only as CoNS or
staphylococci species known to be coagulase negative. Group 4 includes staphylococci identified as Staphylococcus spp
MRSA methicillin-resistant Staphylococcus aureus, MRSP methicillin-resistant Staphylococcus pseudintermedius, MRCoNS methicillin-resistant coagulase
negative staphylococci
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden;
CH, Switzerland; UK, United Kingdom
b95 % CI, 95 % Confidence interval
N, Total number of staphylococci
n tested, number of staphylococci tested for methicillin-resistance within each group
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time periods considered (Table 7). Belgium showed a
significant decrease in E. coli resistance to all antimicro-
bials and an increase in full susceptible isolates.
Denmark (AMC, FLU, SXT), France (3GC, FLU), the
Netherlands (3GC, FLU, SXT, MDR) and Sweden (CN,
MDR) had also significant decreases in E. coli resistance
over time (Table 7). However, the Netherlands (AMC)
and Switzerland (CN) had a significant increase in E. coli
resistance (Table 7). A rising trend was also detected in
Proteus spp. FLU resistance from Belgium (Table 8).
Table 6 Percentage of resistance in Staphylococcus spp. by antimicrobial and country in 2012–2013
Countrya FLU CN SXT
n % R (95 % CI)b
[Stat. Dif.]c
n % R (95 % CI)b
[Stat. Dif.]c
n % R (95 % CI)b
[Stat. Dif.]c
AT 78 26.92
(17.08–36.77)
[a, b]
78 19.23
(10.48–27.98)
[a]
78 20.51
(11.55–29.47)
[a, b]
BE 116 7.76
(2.89–12.63)
[c, d]
107 3.74
(0.14–7.33)
[b]
122 13.11
(7.12–19.10)
[a, b, c]
DK 51 1.96
(0.00–5.77)
[c, e, f]
51 3.92
(0.00–9.25)
[b]
51 0
-
[d]
FR 238 23.53
(18.14–28.92)
[a, g]
237 5.06
(2.27–7.85)
[b]
242 11.57
(7.54–15.60)
[a, c]
DE 55 18.18
(7.99–28.38)
[a, d, g]
55 10.91
(2.67–19.15)
[a, b]
55 23.64
(12.41–34.86)
[b]
EL 10 20.00
(0.00–44.79)
[a, d, e,gN h]
0 -
-
-
9 1R/8S
-
-
IT 19 42.11
(19.90–64.31)
[a]
19 26.32
(6.52–46.12)
[a]
19 63.16
(41.47–84.85)
[e]
NL 364 6.59
(4.04–9.14)
[c, i]
9 1R/8S
-
-
365 11.51
(8.23–14.78)
[c]
PT 6 3R/3S
-
-
7 2R/5S
-
-
7 1R/6S
-
-
RS 0 -
-
-
0 -
-
-
0 -
-
-
ES 13 15.38
(0.00-35.00)
[a, d, e, h, i]
8 0R/8S
-
-
11 18.18
(0.00-40.97)
[a, b, c]
SE 325 1.54
(0.20–2.88)
[f]
325 0
-
[c]
325 2.77
(0.99–4.55)
[d]
CH 41 24.39
(11.25–37.54)
[a, b]
41 9.76
(0.67–18.84)
[a, b]
41 19.51
(7.38–31.64)
[a, b, c]
UK 31 12.90
(1.10–24.70)
[b, c, e, g]
22 4.55
(0.00–13.25)
[a, b, c]
30 16.67
(3.33–30.00)
[a, b, c]
FLU fluoroquinolones, CN gentamicin, SXT trimethoprim/sulfamethoxazole
aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden;
CH, Switzerland; UK, United Kingdom
b95 % CI, 95 % Confidence interval
cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the same letter. Countries were compared by fisher exact test
with an alpha value of 0.05. Countries with less than ten tested isolates were not compared
n, Total number of Staphylococcus spp. tested for the considered antimicrobial category
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Discussion
Published data on antimicrobial resistance in bacteria
isolated from companion animal UTIs over Europe is
scarce [19] and the comparison between studies is
impaired by the use of different inclusion criteria and
different time periods. Moreover, UTI resistance fre-
quencies are usually reported together with susceptibility
data from other sites of infection [11, 28], combining
different bacteria genera [8, 9] and several countries
[29, 30]. These facts impair the establishment of a global
epidemiological overview of UTI bacteria resistance in
Europe. This is the first large study to analyse antimicro-
bial susceptibility data of canine and feline isolates from
several European countries allowing an epidemiological
overview of UTI resistance trends in Europe.
In accordance to previous studies [7–9, 31, 32], E.
coli was the most frequently isolated bacteria in dogs
and cats. Enterococcus presented a significantly higher
frequency in cats and Proteus spp. in dogs. While not
compared in previous studies, this difference could be
expected based on some published data focused on
cats [7, 9] and dogs [32] separately.
One of the most important findings from this study
was the overall higher resistance frequencies found in
the Southern countries (Italy, Greece, Portugal and
Spain) when compared with the Northern countries
(Denmark and Sweden). The lower frequency of anti-
microbial resistance in Northern countries, such as
Sweden, is likely a consequence of the tight regulations
and surveillance on antimicrobial prescribing and resist-
ance in companion animals. In light of the present
results, such strategies could be useful in aiming the
reduction of antimicrobial resistance in the Southern
countries.
Resistance to Beta-Lactams
Amoxicillin-clavulanate
Considering that AMC is one of the most used antimicro-
bials in animals, the levels of resistance detected in this
study are worrisome, especially in the Southern countries.
Previous published reports showed different frequencies
of AMC resistance in E. coli and in Proteus spp. that are
likely due to the fact they report to different time frames
and inclusion criteria [10, 32–37]. In the absence of clin-
ical data it is not possible to know if this resistance relates
to uncomplicated or complicated UTI [19]. Thus, these
results need to be further investigated in order to establish
whether AMC is a suitable empiric therapeutic choice for
companion animals UTI in Southern Europe.
Third generation cephalosporins
Southern countries had also higher levels of resistance to
3GCs. Although Greece was not included due to limited
data, considering that seven out of the nine tested isolates
were resistant to 3GCs, one can expect the prevalence of
3GC resistance to be high. Previous studies in Portugal
found a considerable lower 3GC resistance value (1.4 %)
in E. coli from dogs in earlier years [10]. In the present
work, the lower Swedish results for 3GC resistance in E.
coli and Proteus spp. are in agreement with early studies
[38]. Being of critical importance to humans [39], prudent
use of 3GC is of upmost importance.
Methicillin-resistance
The frequency of methicillin-resistant staphylococci,
especially S. pseudintermedius and CoNS, varied consid-
erably between countries and confirmed previous reports
on a low MRSP prevalence in Scandinavia compared to
elsewhere in Europe [40]. Resistance to methicillin in
Fig. 4 Percentage (%) of Staphylococcus spp. antimicrobial resistance by antimicrobial and country in the years 2012–2013. Countries: AT- Austria;
BE- Belgium; DK- Denmark; FR- France; DE- Germany; EL- Greece; IT- Italy; NL- the Netherlands; PT- Portugal; RS- Serbia; ES- Spain; SE- Sweden;
CH- Switzerland; UK- United Kingdom
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coagulase-positive Staphylococcus (S. aureus and S. pseu-
dintermedius) was detected in this study and is a great
animal and public health concern [41]. Currently, the
recommended methods for the detection of methicillin-
resistance in Staphylococci are manly phenotypic but in
some circumstances the molecular detection of the
mecA gene is clinically and epidemiologically necessary
[22, 23, 42]. This should be taken in consideration for
the harmonization of veterinary susceptibility testing in
Europe.
Resistance to fluoroquinolones
In this study, high resistance frequencies towards the
fluoroquinolones were found in E. coli, Proteus spp and
Staphylococcus spp. isolates in the southern European
countries but also in Proteus spp. from Germany,
Belgium and Switzerland and Staphylococcus spp. from
Austria, Switzerland and France. Several authors [32, 34,
43, 44] have reported lower FLU resistance frequencies
than the ones found in this study, especially regarding
the Southern countries [43, 44]. The results of high
Table 7 Temporal trends of antimicrobial resistance in Escherichia coli by country
Countrya
(Years)
AMC 3GC FLU CN SXT MDR FullS
ORb
(95 % CI)c
P value
ORb
(95 % CI) c
P value
ORb
(95 % CI) c
P value
ORb
(95 % CI) c
P value
ORb
(95 % CI) c
P value
ORb
(95 % CI) c
P value
ORb
(95 % CI) c
P value
BE
(2010–13)
0.787
(0.646–0.960)
0.0180
-
-
-
0.749
(0.635–0.882)
0.0006
0.677
(0.507–0.904)
0.0081
0.796
(0.695–0.912)
0.0010
0.529d
(0.393–0.712)
<0.0001
1.275d
(1.127–1.442)
0.0001
DK
(2008–13)
0.698
(0.500–0.976)
0.0357
0.869
(0.646–1.169)
0.3533
0.742
(0.565–0.976)
0.0325
0.926
(0.620–1.384)
0.7086
0.793
(0.642–0.980)
0.0316
0.874
(0.615–1.242)
0.4528
1.396
(1.156–1.684)
0.0005
FR
(2010–13)
0.885
(0.780–1.005)
0.0606
0.859
(0.749–0.987)
0.0314
0.822
(0.727–0.928)
0.0016
0.938
(0.734–1.200)
0.6121
0.960
(0.853–1.080)
0.4997
0.901
(0.782–1.037)
0.1448
1.112
(1.002–1.233)
0.0456
DE
(2009–13)
1.029
(0.779–1.358)
0.8424
1.076
(0.805–1.438)
0.6211
1.185
(0.912–1.540)
0.2037
0.856
(0.520–1.409)
0.5397
1.040
(0.831–1.302)
0.7317
1.111
(0.801–1.541)
0.5295
0.941
(0.780–1.136)
0.5281
ELe
(2009–13)
1.534
(0.851–2.766)
0.1545
1.083
(0.586–2.003)
0.7992
0.924
(0.630–1.355)
0.6855
-
-
-
0.880
(0.596–1.301)
0.5229
-
-
-
-
-
-
IT
(2009–2013)
1.175
(0.844–1.637
0.3391)
1.017
(0.749–1.383)
0.9127
0.828
(0.629–1.090)
0.1784
1.007
(0.700–1.449)
0.9686
0.769
(0.582–1.016)
0.0645
1.065
(0.761–1.490)
0.7147
1.248
(0.953–1.634)
0.1076
NL
(2008–13)
1.108
(1.026–1.197)
0.0088
0.465
(0.402–0.539)
<0.0001
0.916
(0.841–0.999)
0.0464
0.682
(0.327–1.422)
0.3071
0.917
(0.859–0.978)
0.0083
0.380d
(0.320–0.450)
<0.0001
1.648d
(1494.–1.818)
<0.0001
PT
(2008–13)
1.139
(0.913–1.419)
0.2482
1.187
(0.945–1.492)
0.1411
1.029
(0.823–1.287)
0.8029
1.222
(0.899–1.660)
0.2010
1.087
(0.867–1.364)
0.4680
1.156
(0.898–1.488)
0.2601
0.797
(0.629–1.010)
0.0608
ES
(2010–13)
1.372
(0.855–2.201)
0.1899
1.551
(0.857–2.808)
0.1474
0.801
(0.529–1214)
0.2965
0.859
(0.467–1.578)
0.6238
0.752
(0.489–1.156)
0.1939
1.237
(0.677–2.258)
0.4897
0.944
(0.570–1.564)
0.8234
SE
(2008–13)
0.976
(0.915–1.041)
0.4569
-
-
-
0.980
(0.827–1.147)
0.8018
0.700
(0.562–0.872)
0.0015
0.961
(0.892–1.037)
0.3059
0.697
(0.493–0.985)
0.0407
1.035
(0.965–1.110)
0.3341
CH
(2008–13)
1.143
(0.905–1.445)
0.2621
1.116
(0.861–1.447)
0.4067
1.007
(0.841–1.205)
0.9426
1.493
(1.009–2.208)
0.0451
1.080
(0.901–1.294)
0.4050
1.189
(0.920–1.536)
0.1863
1.025
(0.877–1.197)
0.7594
UK
(2008–13)
1.075
(0.857–1.357)
0.5194
1.106
(0.873–1.400)
0.4041
0.945
(0.739–1.208)
0.6511
1.306
(0.792–2.155)
0.2952
0.972
(0.797–1.185)
0.7778
1.355
(0.954–1.925)
0.0892
1.154
(0.950–1.401)
0.1492
AMC amoxicillin clavulanate, 3GC third generation cephalosporins, FLU fluoroquinolones, CN gentamicin, SXT trimethoprim/sulfamethoxazole, MDR multidrug-
resistant, FullS fully-susceptible
aBE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; ES, Spain; SE, Sweden; CH, Switzerland; UK,
United Kingdom
bOR, Odds ratio
c95 % CI, 95 % Confidence interval
dMDR and FullS temporal trends do not include resistance to 3GC for Belgium and CN for the Netherlands
eData regarding the years 2010 and 2012 were excluded from Greece resistance trends analysis since less than ten isolates were tested in those years
Statistically significant trends are highlighted in bold
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resistance frequencies towards the fluoroquinolones
found in this study are concerning because fluoroquino-
lones are considered a good first choice for pyeloneph-
ritis treatment and should otherwise be used as a second
line antimicrobial [19].
Resistance to folate inhibitors and to aminoglicosides
In this study, resistance to SXT in Europe was high,
especially in E. coli and Proteus spp.. The higher SXT
resistance found in Proteus spp., than in E. coli from
several European countries, is consistent with other re-
ports [34, 36, 45]. Compared with previous studies, these
results show a superior SXT resistance in E. coli and
Proteus spp. from Italy and Portugal [10, 43] and
Staphylococcus spp. from Belgium [36].
Also in agreement to previous studies, gentamicin was
the antimicrobial with lower resistance in E. coli, Proteus
spp. and Staphylococcus spp. all-over Europe [32, 34, 35,
37, 38, 43, 45]. Nevertheless, the distribution seemed to
follow the same pattern, with increased resistance in
Southern over Northern countries.
Multidrug-resistance
Finally, MDR bacteria presented the worst scenario once
again in E. coli from Southern countries and in Proteus
spp. from Portugal. The emergence of MDR bacteria in
companion animals has been previously described [46, 47]
and represents a great therapeutic challenge and public
health concern. However, MDR/FullS frequencies are
seldom reported and published data account for different
antimicrobials, thus impairing any comparisons with the
present results [10, 32, 35, 38, 45].
Trends in antimicrobial resistance
The surveillance of antimicrobial resistance is an import-
ant tool to guide the implementation of antimicrobial
stewardship strategies. In this study, most countries had
no significant changes in antimicrobial resistance over
the time frame considered. Nevertheless, decreasing
trends in antimicrobial resistance were found in E. coli.
These encouraging trends were not detected in AMC
and CN resistance in E. coli from the Netherlands and
Switzerland, respectively, where an increasing trend was
observed. Although no changes over time were detected
in E. coli resistance against AMC and 3CGs in Portugal,
the considerably lower resistance frequencies previously
reported in earlier years [10], point to a possible increas-
ing trend [33]. The same may be the case for E. coli
AMC resistance in Germany and Switzerland [34, 35].
Despite reporting clear trends such as the difference in
resistance between Northern and Southern countries,
data from this study should be interpreted with caution.
Due to the retrospective nature of this study, data on
clinical history such as the type of UTI and previous
antimicrobial treatment were unavailable. Furthermore,
the use of laboratory data may represent a bias towards
resistance, since urine cultures from complicated cases
tend to be requested more often than simple uncompli-
cated UTI [8, 31]. These limitations are not restricted to
certain countries, and are therefore not likely to hamper
comparison of data across borders. Given the limitations
of retrospective studies, a veterinary European surveillance
network gathering data prospectively on antimicrobial
resistance, as well as, on clinical data is of the upmost
importance to facilitate development of national evidence-
based guidelines that take into consideration type of UTI,
local regulations and patterns of antimicrobial resistance.
The use of different susceptibility testing methods and
different clinical breakpoints is considered a major limita-
tion. The lack of harmonization became evident in this
study when trying to compare 3GC and methicillin-
resistance. Although it also happens in the well-established
Table 8 Temporal trends of antimicrobial resistance in Proteus spp. by country
Countrya
(Years)
AMC FLU SXT
ORb (95 % CI)c
P value
ORb (95 % CI) c
P value
ORb (95 % CI) c
P value
BE (2010–13) 0.627 (0.312–1.259)
0.1889
1.292 (1.006–1.659)
0.0450
0.891 (0.726–1.092)
0.2649
FR (2010–13) 0.945 (0.625–1.431)
0.7908
1.004 (0.764–1.319)
0.9770
0.954 (0.756–1.205)
0.6944
NL (2008–13) 1.092 (0.860–1.387)
0.4709
0.970 (0.829–1.135)
0.7067
1.010 (0.903–1.129)
0.8660
SE (2008–13) 0.892 (0.657–1.210)
0.4620
0.884 (0.494–1.583)
0.6788
0.941 (0.759–1.165)
0.5756
AMC amoxicillin clavulanate, FLU fluoroquinolones, SXT trimethoprim/sulfamethoxazole
Statistically significant trends are highlighted in bold
aBE, Belgium; DK, Denmark; FR, France; NL, the Netherlands; SE, Sweden; CH, Switzerland
bOR, Odds ratio
c95 % CI, 95 % Confidence interval
Marques et al. BMC Veterinary Research  (2016) 12:213 Page 14 of 17
EARS network reports of resistance on bacteria from hu-
man invasive infections [18], this limitation weakens the
comparison of resistance between countries in the present
and future surveillance studies. This harmonization would
allow future within and between countries resistance fre-
quencies comparisons over time and would also provide
relevant information on the impact of different antimicro-
bial usage policies. Thus, the authors agree that the
harmonization of methods and interpretative criteria in vet-
erinary medicine should be a priority. The role of the new
veterinary committee on antimicrobial susceptibility testing
VetCAST [48] may be crucial in this harmonization
process. Despite these limitations, the results from this
study provide relevant and updated information on the
current antimicrobial resistance in UTI bacteria from com-
panion animals in Europe. Similar studies should also be
conducted regarding other types of infection to improve
the awareness on the European distribution of antimicro-
bial resistance in companion animals. Ideally, monitoring of
companion animal antimicrobial resistance should be im-
plemented in Europe, as it is the case for food producing
animals. Such surveillance would provide crucial informa-
tion to promote the appropriate use of antimicrobial and
therefore limit the spread of resistance.
Conclusions
This work brings new insights into the current scenario
of the European antimicrobial resistance bacteria iso-
lated from companion animals with UTI. An important
finding from this study was the higher frequency of
resistance in Southern European countries (Italy, Greece,
Spain, Portugal) when compared to Northern European
countries (Denmark, Sweden). Furthermore, there is an
evident need to harmonize methods and interpretative
criteria in veterinary medicine. Given the limitations of
retrospective studies, an European surveillance network
gathering data on antimicrobial resistance is of the
upmost importance to facilitate the development of
national evidence-based guidelines.
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